Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
DEXFERRUM vs SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Sodium ferric gluconate complex in sucrose provides elemental iron for hemoglobin synthesis and replenishes iron stores in iron-deficient states. The iron complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
125 mg elemental iron (10 mL) intravenously over at least 10 minutes, given at sequential dialysis sessions to a cumulative total dose of 1000 mg elemental iron.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Terminal elimination half-life is approximately 6 hours for the iron-sucrose complex; clinical context: indicates redistribution and utilization for erythropoiesis, with full hemoglobin correction over weeks.
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Primarily excreted via feces (93%) as non-absorbed iron; renal elimination of absorbed iron is minimal (<1%).
Category C
Category C
Iron Supplement
Iron Supplement